Health Headline: Stony Brook Heart Institute delivers world’s 1st commercial plozasiran treatment for patients with rare lipid disease
Stony Brook Heart Institute’s Center for Advanced Lipid Management has achieved a historic global milestone, becoming the first center in the world to administer a commercial dose of plozasiran, the newly approved RNA-interference therapy for familial chylomicronemia syndrome.
Share:
More Stories
Click HERE for more info.
